Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-870,893 in Advanced Solid Tumors
NCT02225002Phase 1Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2004
- Primary completion
- Feb 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selicrelumab in solid tumor, sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 2 years. Started Jan 2004; status: completed.
02
Drugs
selicrelumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02225002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225002.